|By PR Newswire||
|August 27, 2013 08:02 AM EDT||
ROCVKILLE, Md., Aug. 27, 2013 /PRNewswire-USNewswire/ -- Major depressive disorder (MDD) is a fairly common and serious condition among children and adolescents. About 11 percent of adolescents have a depressive disorder by age 18 according to the National Comorbidity Survey-Adolescent Supplement (NCS-A). MDD is more than just feeling a little sad or having a rough day. People with MDD have feelings of sadness that can last a long time. However, a new clinical research study, called STEADi (Study To Evaluate an Adolescent Depression Investigational drug), is now seeking patients to evaluate the safety of an investigational drug and to see if it works for adolescents who have MDD.
Symptoms of MDD include feelings of worthlessness and low self-esteem. MDD in adolescents can be chronic and recurrent, and there are currently only a few treatments available to treat younger patients who have MDD.
The STEADi clinical research study is being conducted to test the safety and efficacy of an investigational drug to see if it may be a potential new treatment option for adolescents ages 12 to 17 with MDD. The investigational drug being studied is approved by the U.S. Food and Drug Administration (FDA) and available by prescription as a treatment for adults with depression. It is not approved as a treatment for children or adolescents with depression; therefore, it is considered investigational in this clinical research study.
Clinical research studies test the safety of investigational treatments for diseases and conditions and see if they work. People volunteer to participate in clinical studies, and these studies play an important role in the development of medications. Many drugs, therapies, and devices that are used today are the result of past clinical studies.
To learn more about the STEADi clinical research study, to find doctors who are conducting the study, or to find out if you may be eligible to participate, visit www.SteadiMDDStudy.com or call 877-904-8735.
SOURCE STEADi clinical research study